The latest price target for CARISMA Therapeutics (NASDAQ:CARM) was reported by D. Boral Capital on November 11, 2024. The analyst firm set a price target for $24.00 expecting CARM to rise to within 12 months (a possible 2508.70% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for CARISMA Therapeutics (NASDAQ:CARM) was provided by D. Boral Capital, and CARISMA Therapeutics maintained their buy rating.

There is no last upgrade for CARISMA Therapeutics

There is no last downgrade for CARISMA Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CARISMA Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CARISMA Therapeutics was filed on November 11, 2024 so you should expect the next rating to be made available sometime around November 11, 2025.

While ratings are subjective and will change, the latest CARISMA Therapeutics (CARM) rating was a maintained with a price target of $24.00 to $24.00. The current price CARISMA Therapeutics (CARM) is trading at is $0.92, which is out of the analyst’s predicted range.